Gabrielle Boyd, OD
Optometrist · Shreveport, LANPI 1730687260
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 164 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 25.6% of the total. 2025 is the largest year on record at $1,768, 5.7 times the $308 reported in 2019.
Across 164 payments — averaging $31.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Alcon$899
- Biotissue Holdings Inc.$659
- Tarsus Pharmaceuticals, Inc.$443
- Oyster Point Pharma, Inc.$296
- Novartis$241
- plus $1K from 13 others
What the payments were for
- Speaking & faculty fees$260%
- Food & beverage$5,12199%
- Other$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 40 | $1,326 |
| Alcon | 29 | $899 |
| Biotissue Holdings Inc. | 14 | $659 |
| Tarsus Pharmaceuticals, Inc. | 12 | $443 |
| Oyster Point Pharma, Inc. | 13 | $296 |
| Novartis | 8 | $241 |
| Rxsight Inc | 6 | $223 |
| Kala Pharmaceuticals, Inc. | 6 | $221 |
| Mallinckrodt Hospital Products Inc. | 8 | $214 |
| Amgen(2 entities) | 10 | $195 |
| Bausch & Lomb Americas Inc. | 6 | $113 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $100 |
| Harrow Eye, LLC | 3 | $75 |
| Thea Pharma Inc. | 3 | $62 |
| Apellis Pharmaceuticals, Inc. | 1 | $27 |
| Welch Allyn | 1 | $25 |
| Aerie Pharmaceuticals, Inc. | 1 | $21 |
| Sight Sciences, Inc. | 1 | $18 |
| Eyevance Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,171 in reported general payments places this provider in the 85th percentile of 500 optometrist providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 75 | $120,135 |
| RestasisCyclosporine | 40 | $58,576 |
| XdemvyLotilaner | 19 | $35,270 |
| TyrvayaVarenicline Tartrate | 24 | $25,202 |
| Cyclosporine | 17 | $16,210 |
| MieboPerfluorohexyloctane/Pf | 13 | $14,600 |
| RocklatanNetarsudil Mesylat/Latanoprost | 15 | $10,119 |
| LumiganBimatoprost | 22 | $8,895 |
| Alphagan PBrimonidine Tartrate | 20 | $6,952 |
| Prednisolone Acetate | 108 | $4,892 |
| Brimonidine Tartrate | 93 | $4,263 |
| Latanoprost | 531 | $3,713 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 13 | $3,665 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 155 | $2,004 |
| Timolol Maleate | 148 | $1,565 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $113 | $134,73588 claims |
| AbbVieRestasis, Lumigan, Alphagan P | $1,326 | $74,42382 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $443 | $35,27019 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $296 | $25,20224 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $21 | $10,11915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 500 optometrist providers in Louisiana.
Other optometrist in Shreveport
- Pamela TheriotShreveport$207K
- Stephen LewisShreveport$17K
- Sam SilverblattShreveport$6K
- Christine DavisShreveport$6K
- Joshua DavidsonGonzales$189K
- Jeffrey WilhiteMarrero$86K
- Christopher WrotenHammond$59K
- James LamarNew Orleans$45K
- John McCallLogansport$32K
- Robert KellyMarrero$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.